FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 08/2024”. The Monitor is a month-to-month revealed overview of enterprise capital developments within the European Healthcare & Life Sciences sector.
As of the tip of August 2024 we recognized the next present VC developments in Europe:
- Whole Healthcare & Life Sciences funding reached EUR 5,581m
- Biotech acquired 58% of the overall funding quantity (EUR 3,218m) with oncology being the main indication (48%)
- August noticed little or no VC exercise in Europe (EUR 133m) with Healx (United Kingdom) securing the best transaction quantity with EUR 43m, adopted by Hexarad (United Kingdom) with EUR 13m and Vandria (Switzerland) with EUR 11m
- Normal Atlantic (United States) is probably the most lively investor (by deal quantity), adopted by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To entry the total report, please click on right here.
By Mathias Klozenbücher and Johannes Hyperlink